Bio Pharma

Teriparatide (API) to accelerate osteoporosis therapy

Background

  • Teriparatide is a Recombinant DNA form of parathyroid hormone consisting of the 34 amino acids bioactive portion of the hormone, used in the treatment osteoporosis.
  • Teriparatide is sold by Eli Lilly and Company under the brand name Forteo.
  • Our technology on Teriparatide would benefit many pharma majors to decrease their cost of peptides production.

Salient features Lorven’s Teriparatide

  • Application ready Teriparatide Biosimilar from E. coli.
  • High pure (96%), available at an economical price .
  • Lorven’s Teriparatide is expressed in E. coli expression system
  • Yields up to gm/lit.
  • Optimized downstream processing.

Product Quality

  • Biosimilar to Teriparatide (Novo Nordisk).
  • 100% native confirmation.
  • Functionally active peptide.
  • Free from animal-derived components.

Safety

  • E. coli : Genetically highly amenable host organism with BSL-1 maintenance.

IP

  • Patent Application Under process:
  • Title: Process for improved expression of biologically active Teriparatide in E. coli expression system by strain engineering.